menu search

FOLD / Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease

Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease
Amicus Therapeutics Inc (NASDAQ: FOLD) has announced additional results from a Phase 1/2 clinical study of AT-GAA in adult patients with Pompe disease. Study participants treated with AT-GAA for up to 36 months showed persistent and durable effects on six-minute walk test (6MWT). Read More
Posted: Mar 16 2022, 10:07
Author Name: Benzinga
Views: 111993

FOLD News  

Amicus Therapeutics: The Right Play Now

By Seeking Alpha
October 31, 2023

Amicus Therapeutics: The Right Play Now

Amicus Therapeutics, Inc. is a commercial-stage biotech company focused on developing therapies for rare diseases. The company recently received FDA a more_horizontal

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

By Zacks Investment Research
September 29, 2023

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease. more_horizontal

3 Stocks Worth a Watch for Solid Earnings Acceleration

By Zacks Investment Research
September 20, 2023

3 Stocks Worth a Watch for Solid Earnings Acceleration

Some of the notable companies to have witnessed solid earnings acceleration as of now are Amicus Therapeutics (FOLD), Genius Sports (GENI) and Viad (V more_horizontal

Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance

By Zacks Investment Research
August 9, 2023

Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance

Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises i more_horizontal

Amicus Therapeutics Inc. (FOLD) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

Amicus Therapeutics Inc. (FOLD) Q2 2023 Earnings Call Transcript

Amicus Therapeutics Inc. (NASDAQ:FOLD ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Andrew Faughnan - Vice Presiden more_horizontal

Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)

By Zacks Investment Research
August 7, 2023

Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

3 Top Breakout Stocks to Invest in for Excellent Returns

By Zacks Investment Research
August 3, 2023

3 Top Breakout Stocks to Invest in for Excellent Returns

First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today. more_horizontal

Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023

By GlobeNewsWire
July 31, 2023

Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023

PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and li more_horizontal


Search within

Pages Search Results: